2017 Confidentiality Litigation Settlement 
Trading Secrets
FEBRUARY 5, 2024
In 2017, Life Spine entered into various agreements with Aegis by which Aegis would sell and distribute ProLift devices while maintaining as confidential all proprietary information related to the devices. Litigation continued for years, with Aegis raising unsuccessful counterclaims.
LexBlog IP
FEBRUARY 5, 2024
In 2017, Life Spine entered into various agreements with Aegis by which Aegis would sell and distribute ProLift devices while maintaining as confidential all proprietary information related to the devices. Litigation continued for years, with Aegis raising unsuccessful counterclaims.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LexBlog IP
APRIL 13, 2023
Patent trolls leverage the litigation system to negotiate settlements for less than the cost of defending against a lawsuit. Patent trolls normally prefer to keep their operations as confidential as possible, as I wrote about in connection with the District of Delaware. 3d 1369, 1383 (2017). .” How can you tell?
Technology & Marketing Law Blog
JUNE 8, 2024
” That prompted this litigation. CV H-17-1068, 2017 WL 2957912, at *8 (S.D. July 11, 2017) (holding that “the mere purchase of AdWords alone, without directing a consumer to a potentially confusing web page, is not sufficient for a claim of trademark infringement,” citing Mary Kay, 601 F. ” Uh oh. See Tempur-Pedic N.
JIPL Online
MARCH 15, 2021
Then, the post will predict how Netflix may shift its content practices, defense strategies, and settlement tactics as a result of their past litigation successes in copyright actions. SETTLEMENT CASES. 9] Both parties reached an amicable settlement. [10] 9] Both parties reached an amicable settlement. [10]
LexBlog IP
AUGUST 4, 2021
On July 20, 2021, after nearly four years of litigation, Johnson & Johnson (J&J) and Pfizer have agreed to dismiss all claims asserted in the antitrust suit brought by Pfizer in the Eastern District of Pennsylvania regarding Remicade (infliximab). According to J&J , “The U.S. competition-based model is working.
The IPKat
JUNE 22, 2023
Mellor J, the Judge, explained that in very general terms he adopted the same approach as that of Birss J in Unwired Planet v Huawei [2017] EWHC 711 (Pat) ([42]). The Judge decided to adopt the same approach as in Unwired Planet v Huawei [2017] EWHC 711 (Pat) and in the US judgment TCL v Ericsson (C.D. 21, 2017) (Selna, J.)
Expert insights. Personalized for you.
52 
Let's personalize your content